Differential response in choice reaction time following apomorphine based on prior dopaminergic treatment

Acta Neurologica Scandinavica

Volumn 109, Issue 5, 2004, Pages 348-354

  Muller T ^a   Benz, S ^a   Bornke C ^a   Przuntek, H ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

Apomorphine; Choice reaction time; Parkinson's disease

Indexed keywords

APOMORPHINE; DOPAMINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; LOCOMOTION; MALE; PARKINSON DISEASE; RECEPTOR BINDING; RESPONSE TIME; SEDATION; TASK PERFORMANCE;

ADULT; AGED; ANTIPARKINSON AGENTS; APOMORPHINE; AUTORECEPTORS; CHOICE BEHAVIOR; DOPAMINE AGENTS; DOUBLE-BLIND METHOD; DRUG TOLERANCE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; LONG-TERM CARE; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PREMEDICATION; PSYCHOMOTOR PERFORMANCE; REACTION TIME; RECEPTORS, PRESYNAPTIC;

EID: 2342574169     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1600-0404.2003.00231.x     Document Type: Article

References (50)

1. CLAUS JJ, MOHR E. Attentional deficits in Alzheimer's, Parkinson's, and Huntington's diseases. Acta Neurol Scand 1996;93:346-51.
2. EVARTS EV, TERAVAINEN H, CALNE DB. Reaction time in Parkinson's disease. Brain 1981;104:167-86.
3. JAHANSHAHI M, BROWN RG, MARSDEN CD. The effect of withdrawal of dopaminergic medication on simple and choice reaction time and the use of advance information in Parkinson's disease. J Neurol Neurosurg Psychiatry 1992;55:1168-76.
4. JAHANSHAHI M, BROWN RG, MARSDEN CD. Simple and choice reaction time and the use of advance information for motor preparation in Parkinson's disease. Brain 1992; 115:539-64.
5. JAHANSHAHI M, BROWN RG, MARSDEN CD. A comparative study of simple and choice reaction time in Parkinson's, Huntington's and cerebellar disease. J Neurol Neurosurg Psychiatry 1993;56:1169-77.
6. JORDAN N, SAGAR HJ, COOPER JA. Cognitive components of reaction time in Parkinson's disease. J Neurol Neurosurg Psychiatry 1992;55:658-64.
7. LALONDE R, BOTEZ-MARQUARD T. The neurobiological basis of movement initiation. Rev Neurosci 1997;8:35-54.
8. MONTGOMERY EB JR, GORMAN DS, NUESSEN J. Motor initiation versus execution in normal and Parkinson's disease subjects. Neurology 1991;41:1469-75.
9. ZAPPIA M, MONTESANTI R, COLAO R, QUATTRONE A. Usefulness of movement time in the assessment of Parkinson's disease. J Neurol 1994;241:543-50.
10. PRASHER D, FINDLEY L. Dopaminergic induced changes in cognitive and motor processing in Parkinson's disease: an electrophysiological investigation. J Neurol Neurosurg Psychiatry 1991;54:603-9.
11. WANG J, THOMAS JR, STELMACH GE. A meta-analysis on cognitive slowing in Parkinson's disease: are simple and choice reaction times differentially impaired? Parkinsonism Relat Disord 1998;4:17-29.
12. PULLMAN SL, WATTS RL, JUNCOS JL, SANES JN. Movement amplitude choice reaction time performance in Parkinson's disease may be independent of dopaminergic status. J Neurol Neurosurg Psychiatry 1990;53:279-83.
13. PULLMAN SL, WATTS RL, JUNCOS JL, CHASE TN, SANES JN. Dopaminergic effects on simple and choice reaction time performance in Parkinson's disease. Neurology 1988; 38:249-54.
14. MÜLLER T, BENZ S, PRZUNTEK H. Choice reaction time after levodopa challenge in parkinsonian patients. J Neurol Sci 2000;181:98-103.
15. MÜLLER T, BENZ S, BÖRNKE C. Delay of simple reaction time after levodopa intake. Clin Neurophysiol 2001; 112:2133-7.
16. KULISEVSKY J, AVILA A, BARBANOJ M, ANTONIJOAN R, BERTHIER ML, GIRONELL A. Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels. Brain 1996;119:2121-32.
17. STRAFELLA AP, VALZANIA F, NASETTI SA et al. Effects of chronic levodopa and pergolide treatment on cortical excitability in patients with Parkinson's disease: a transcranial magnetic stimulation study. Clin Neurophysiol 2000;111:1198-202.
18. DUBINSKY RM, GRAY C, HUSTED D et al. Driving in Parkinson's disease. Neurology 1991;41:517-20.
19. FERREIRA JJ, GALITZKY M, MONTASTRUC JL, RASCOL O. Sleep attacks and Parkinson's disease treatment [letter]. Lancet 2000;355:1333-4.
20. FRUCHT SJ, GREENE PE, FAHN S. Sleep episodes in Parkinson's disease: a wake-up call [editorial]. Mov Disord 2000; 15:601-3.
21. HUGHES AJ, LEES AJ, STERN GM. Challenge tests to predict the dopaminergic response in untreated Parkinson's disease. Neurology 1991;41:1723-5.
22. HUGHES AJ, DANIEL SE, KILFORD L, LESS AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
23. FAHN S, ELTON R. Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent developments in Parkinson's disease II. New York: Macmillan, 1987:153-63.
24. COOPER JA, SAGAR HJ, TIDSWELL P, JORDAN N. Slowed central processing in simple and go/no-go reaction time tasks in Parkinson's disease. Brain 1994;117:517-29.
25. SOLIVERI P, BROWN RG, JAHANSHAHI M, MARSDEN CD. Effect of practice on performance of a skilled motor task in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1992;55:454-60.
26. RAFAL RD, FRIEDMAN JH, LANNON MC. Preparation of manual movements in hemiparkinsonism. J Neurol Neurosurg Psychiatry 1989;52:399-402.
27. KUHN W, HEYE N, MÜLLER T et al. The motor performance test series in Parkinson's disease is influenced by depression. J Neural Transm 1996;103:349-54.
28. KULISEVSKY J, GARCIA-SANCHEZ C, BERTHIER ML et al. Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients. Mov Disord 2000;15: 613-26.
29. MÜLLER T, WOITALLA D, SAFT C, KUHN W. Levodopa in plasma correlates with body weight of parkinsonian patients. Parkinsonism Relat Disord 2000;6:171-3.
30. HARRISON J, HENDERSON L, KENNARD C. Abnormal refractoriness in patients with Parkinson's disease after brief withdrawal of levodopa treatment. J Neurol Neurosurg Psychiatry 1995;59:499-506.
31. ZAPPIA M, MONTESANTI R, COLAO R et al. Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease. Mov Disord 1997;12:103-6.
32. WILCOX RE, SPIRDUSO WW. Apomorphine doses impair the reaction time of fast reacting but not slow reacting rats. Psychopharmacology (Berl) 1988;95:276-9.
33. RUZICKA E, ROTH J, SRACKOVA N, MECIR P, JECH R. Apomorphine induced cognitive changes in Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:998-1001.
34. PARKES JD. Domperidone and Parkinspn's disease. Clin Neuropharmacol 1986;9:517-32.
35. FRIEDMAN JJ, TEMPORINI H, DAVIS KL. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry 1999;45:1-16.
36. IVERSEN SD. The pharmacology of memory. C R Acad Sci III 1998;321:209-15.
37. YANG CR, MOGENSON GJ. Dopaminergic modulation of cholinergic responses in rat medial prefrontal cortex: an electrophysiological study. Brain Res 1990;524:271-81.
38. CORSINI GU, DEL ZOMPO M, MANCONI S, PICCARDI MP, ONALI PL, MANGONI A. Evidence for dopamine receptors in the human brain mediating sedation and sleep. Life Sci 1977;20:1613-8.
39. PIRKER W, HAPPE S. Sleep attacks in Parkinson's disease [letter; comment]. Lancet 2000;356:597-8.
40. GOREN JL, FRIEDMAN JH. Yawning as an aura for an L-dopainduced "on" in Parkinson's disease. Neurology 1998; 50:823-4.
41. ARGIOLAS A, MELIS MR, GESSA GL. Yawning: neurochemistry, physiology and pathology. Cephalalgia 1987;7(Suppl 6):131-7.
42. NISHINO S, ARRIGONI J, VALTIER D et al. Dopamine D2 mechanisms in canine narcolepsy. J Neurosci 1991;11: 2666-71.
43. LIN JS, SAKAI K, JOUVET M. Evidence for histaminergic arousal mechanisms in the hypothalamus of cat. Neuropharmacology 1988;27:111-22.
44. GOODCHILD RE, COURT JA, HOBSON I et al. Distribution of histamine H3-receptor binding in the normal human basal ganglia: comparison with Huntington's and Parkinson's disease cases. Eur J Neurosci 1999;11:449-56.
45. ANDREU N, CHALE JJ, SENARD JM, THALAMAS C, MONTASTRUC JL, RASCOL O. L-Dopa-induced sedation: a double-blind cross-over controlled study versus triazolam and placebo in healthy volunteers. Clin Neuropharmacol 1999;22: 15-23.
46. MONTASTRUC JL, LLAU ME, SENARD JM, TRAN MA, RASCOL O, MONTASTRUC P. A study of tolerance to apomorphine. Br J Pharmacol 1996;117:781-6.
47. CLARKE CE, DAVIES P. Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 2000;69:590-4.
48. EKESBO A, RYDIN E, TORSTENSON R, SYDOW O, LAENGSTROM B, TEDRO J. Dopamine autoreceptor function is lost in advanced Parkinson's disease. Neurology 1999;52:120-5.
49. GORDON AM, REILMANN R. Getting a grasp on research: does treatment taint testing of parkinsonian patients? [letter]. Brain 1999;122(Pt 8):1597-8.
50. GRANDAS F, GANCHER ST, RODRIGUEZ M, LERA G, NUTT JG, OBESO JA. Differences in the motor response to apomorphine between untreated and fluctuating patients with Parkinson's disease. Clin Neuropharmacol 1992;15:13-18.